Telix Pharmaceuticals Ltd (TLX) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

Low Risk

Limited dilution potential

Last updated: February 24, 2025

Risk Assessment Details

Potential Dilution: 0.0% of current shares

Recent Dilution: 0% (2 years)

Historical Dilution Factor: minimal recent dilution

Outstanding Shares

330M

Potential Supply

Additional shares possible

Splits

None

Past 2 years

Summary

TLX currently has 335M outstanding shares. with minimal authorized share overhang for future dilution. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding
Feb 24, 2025	20-F filing \| 334.7M shares outstanding	330M
Jun 14, 2024	RW filing: Telix Pharmaceuticals Limited is withdrawing its Registration Statement on Form F-1 (File No. 333-279471) due to unfavorable market conditions and the Company's determination that the registration of its securities is not in its best interests at this time.	N/A
May 17, 2024	F-1 filing: This F-1 filing relates to a proposed public offering of American Depositary Shares (ADSs) by Telix Pharmaceuticals Limited, with Jefferies, Morgan Stanley, Truist, and William Blair acting as underwriters. It includes agreements regarding lock-up periods, future reports to representatives, investment limitations, and indemnification.	N/A

Back to TLX Details